Skip to content
Demo
‹ Back to IndustriesSciences

The Biggest Events This Week in B2B

Industrials lead the way this week with FABTECH taking place in Chicago, Illinois from November 11-14. FABTECH is North America’s largest metal forming, fabricating, welding and finishing event, so expect more coverage from the show as it unfolds. Also running from November 11-14 is Teams ’19. The conference focuses on sports-event management and this year…

This story was produced through MarketScale. See how Sciences teams put it to work with Executive Thought Leadership.

By Geoff Short · · CincinnatiFabtechLas VegasLuke Dollar
Share

Key takeaways

01

Industrials lead the way this week with FABTECH taking place in Chicago, Illinois from November 11-14.

02

FABTECH is North America’s largest metal forming, fabricating, welding and finishing event, so expect more coverage from the show as it unfolds.

03

Also running from November 11-14 is Teams ’19.

Free workspace

Turn your Sciences expertise into content.

Record interviews, organize footage, and write with AI on a free trial of the MarketScale platform for qualifying companies. No demo required, no credit card.

Try it Free

Industrials lead the way this week with FABTECH taking place in Chicago, Illinois from November 11-14.

FABTECH is North America’s largest metal forming, fabricating, welding and finishing event, so expect more coverage from the show as it unfolds.

Also running from November 11-14 is Teams ’19.

The conference focuses on sports-event management and this year it will take place in Anaheim, California.

The conference is also an important one for food and beverage hospitality professionals.

Sports-related travel and events are responsible for 88 million hotel room nights and $31 billion in direct spending each year, according to the conference.

And lastly, the National Science Teaching Association is hosting a conference in Cincinnati, Ohio from November 14-16.

The event’s keynote speaker is Luke Dollar, National Geographic explorer and adjunct professor at Duke University.

Attendees will be able to choose among three major conference tracks depending on their specific goals, so there should be something for everyone this week.

Your experts belong here

Every story in MarketScale Sciences starts with a company putting its lab directors, applications scientists, and field specialists on the record. Buyers are already reading this topic. The only question is whose experts they find.

Lab and research buyers verify before they trial, and your scientists give them something credible to verify against.

Book DemoSee how it works15 minutes, straight to a calendar.

About the author

GS
Geoff Short
B2B Weekly

The week in Sciences, and sixteen other industries, every Monday.

Ten stories, one-line takes, five minutes. Free.

Sciences: are you visible to AI?

Before they reach out, Sciences buyers ask AI engines which vendors to trust. Explore how your experts, customers, and partners can become useful content for buyers and AI search.

Book a Demo →Talk to Sales

Free Trial

You just read one Sciences expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your lab directors, applications scientists, and field specialists into the articles, video, and social content Sciences buyers are searching for. Start a free trial and see it with your own people. For qualifying companies, no credit card, no demo required.

Book a Demo →Try it Free

NPS +73 · 1,000+ creators · 38+ countries

What your free trial includes

Hands-on access to the MarketScale platform
Media requests to your crowd, remote recording, AI writing tools
No demo required. No credit card.
For qualifying companies. Company confirmation required.

More Sciences Insights

Simtra opens $250 million-plus Bloomington building with three sterile filling lines

Simtra opens $250 million-plus Bloomington building with three sterile filling lines

Simtra BioPharma Solutions opened Building H, a $250 million-plus addition to its Bloomington, Indiana campus, featuring two syringe lines and a vial line with lyophilizers. The CDMO plans to expand from 11 to 18 filling lines by 2027. Extra sites reduce supply risk only when products are qualified at both locations.

  • 01Simtra's network is set to grow from 11 to 18 filling lines across Indiana and Germany by 2027, a published capacity timeline sponsors can plan tech transfers against.
  • 02A second fill site cuts supply risk only after a product has been validated there; for biologics that means process validation, comparability work and regulatory filings first.
  • 03Programs whose real exposure sits in concentrated starting-material supply gain little from added fill-finish redundancy, however well the new lines are built.

Nov 13, 2026

Agilent's new 5987A GC/MS takes aim at costly sample reruns

Agilent's new 5987A GC/MS takes aim at costly sample reruns

Agilent’s 5987A GC/MSD adds vendor-claimed up to 25% faster scanning and a wider detector range alongside GC Assist diagnostics tracking 60-plus parameters. Its design focuses on taking injections out of workflows to limit reruns. With helium spot prices reportedly doubling after the March 2026 disruption, avoided reruns can save gas, but EPA criteria checks and ISO/IEC 17025 verification still come first.

  • 01Injection-cutting features can matter most: MassHunter’s simultaneous dSIM/Scan to combine SIM quantitation and library-searchable full scan in one run, and Agilent’s claim of an order-of-magnitude wider dynamic range that could reduce dilution reinjections if it holds up in routine use.
  • 02Onboard diagnostics pay back unevenly. Labs that find faults by failing QC batches stand to gain the most, while labs on comprehensive service contracts may mainly change which contract tier they buy.
  • 03The up-to-40% energy cut applies with the IDP-4 pump, so bid scoring should confirm the quoted configuration before crediting the savings.

Nov 10, 2026

Adding Genmab's petosemtamab to Keytruda cut head and neck cancer death risk in half

Adding Genmab's petosemtamab to Keytruda cut head and neck cancer death risk in half

Genmab's petosemtamab, added to Merck's Keytruda, cut the risk of death by 50% in 699 first-line head and neck cancer patients. The trial held regardless of HPV status. Full data will be presented at an upcoming medical meeting.

  • 01In a cancer where median survival runs about 10 to 12 months, adding petosemtamab to Keytruda halved the risk of death at the first interim look.
  • 02The benefit held regardless of HPV status, supporting use in PD-L1-positive patients without separating by HPV status.
  • 03The figure to watch at the full-data presentation is median overall survival in each arm, because the topline release reports only the hazard ratio.

Nov 9, 2026

Explore More Sciences Insights

Read more expert perspectives from across Sciences.

Browse Sciences Hub

About the Expert

GS
Geoff Short

For Sciences teams

See how Sciences teams use MarketScale →

Executive Thought Leadership

Explore Channels

Industry news, analysis, and expert perspectives

Professional AV›Engineering & Construction›Education Technology›Healthcare›Energy›Software & Technology›Retail›Business Services›Industrial IoT›Sports & Entertainment›Transportation›Sciences›Building Management›Food & Beverage›Architecture & Design›Hospitality›Marketing Tech›
Keep exploring

More from Sciences

Sciences hubMore expert Sciences coverage.Explore →Executive Thought LeadershipPut researchers on the record.Explore →FinThriveComplex topics, made clear.Explore →State of GEO & AI VisibilityHow B2B brands get cited by AI search.Explore →

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Sciences and beyond.

Book a Demo

Or call us. No forms required. We pick up. 214-945-2512